We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
A joint FDA Nonprescription Drugs and Endocrinologic and Metabolic Advisory Committee voted 10–2 with one abstention recommending the FDA not approve Merck’s OTC-switch application for statin Mevacor.